Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group
Authors:
- Louise KlokkerLKLouise Klokker
- Peter TugwellPTPeter Tugwell
- Daniel E. FurstDFDaniel E. Furst
- Dan DevoeDDDan Devoe
- Paula WilliamsonPWPaula Williamson
- Caroline B. TerweeCTCaroline B. Terwee
- Maria E. Suarez-AlmazorMSMaria E. Suarez-Almazor
- Vibeke StrandVSVibeke Strand
- Thasia WoodworthTWThasia Woodworth
- Amye L. LeongALAmye L. Leong
- Niti GoelNGNiti Goel
- Maarten BoersMBMaarten Boers
- 15 October 2016
- journal article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 44 (12) , 1916-1919
Abstract
Objective.: Failure to report harmful outcomes in clinical research can introduce bias favoring a potentially harmful intervention. While core outcome sets (COS) are available for benefits in randomized controlled trials in many rheumatic conditions, less attention has been paid to safety in such COS. The Outcome Measures in Rheumatology (OMERACT) Filter 2.0 emphasizes the importance of measuring harms. The Safety Working Group was reestablished at the OMERACT 2016 with the objective to develop a COS for assessing safety components in trials across rheumatologic conditions.Methods.: The safety issue has previously been discussed at OMERACT, but without a consistent approach to ensure harms were included in COS. Our methods include (1) identifying harmful outcomes in trials of interventions studied in patients with rheumatic diseases by a systematic literature review, (2) identifying components of safety that should be measured in such trials by use of a patient-driven approach including qualitative data collection and statistical organization of data, and (3) developing a COS through consensus processes including everyone involved.Results.: Members of OMERACT including patients, clinicians, researchers, methodologists, and industry representatives reached consensus on the need to continue the efforts on developing a COS for safety in rheumatology trials. There was a general agreement about the need to identify safety-related outcomes that are meaningful to patients, framed in terms that patients consider relevant so that they will be able to make informed decisions.Conclusion.: The OMERACT Safety Working Group will advance the work previously done within OMERACT using a new patient-driven approach.Keywords
This publication has 17 references indexed in Scilit:
- Choosing Important Health Outcomes for Comparative Effectiveness Research: An Updated Review and User SurveyPLOS ONE, 2016
- Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0Journal of Clinical Epidemiology, 2014
- Updated Method Guidelines for Cochrane Musculoskeletal Group Systematic Reviews and MetaanalysesThe Journal of Rheumatology, 2013
- Enhancing the reporting and transparency of rheumatology research: a guide to reporting guidelinesArthritis Research & Therapy, 2013
- A first step to assess harm and benefit in clinical trials in one scaleJournal of Clinical Epidemiology, 2010
- Guidance for Developers of Health Research Reporting GuidelinesPLOS Medicine, 2010
- How to Ascertain Drug Safety in the Context of Benefit. Controversies and Concerns: Table 1.The Journal of Rheumatology, 2009
- Observations from the OMERACT Drug Safety Summit, May 2008The Journal of Rheumatology, 2009
- Systematic reviews of adverse effects: framework for a structured approachBMC Medical Research Methodology, 2007
- Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT StatementAnnals of Internal Medicine, 2004